Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs Quantumscape Corp (QS) Price & Performance

Amgen, Inc.Trade
Quantumscape CorpTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Quantumscape Corp — how do they compare? Amgen, Inc. trades at $412.77 (market cap $224.14B), while Quantumscape Corp trades at $6.38 (market cap $3.90B). The key difference: Amgen, Inc. is far larger — about 57.5× Quantumscape Corp's market cap, and Amgen, Inc. pays a 2.43% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals.

AMGNQS
Market Cap
$224.14B$3.90B
Sector
HealthConsumer Cyclical
52-Week High
$417.20$18.44
52-Week Low
$271.18$4.89
Enterprise Value
$267.45B$3.11B
Dividend Yield
2.43%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About Quantumscape Corp

QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.

Read more on QS